Evidence map›Paper›PMID 40134635›Full record

Trial reportOpen forum infectious diseases2025

Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.

Charlotte-Paige Rolle, José R Arribas, Roberto Ortiz, Mark Underwood, Chris M Parry, Richard Grove, V Paul DiMondi, Bryn Jones, Michelle Kisare

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Charlotte-Paige RolleOrlando Immunology Center, Orlando, Florida, USA.ORCID https://orcid.org/0000-0002-6444-2225
José R ArribasDepartment of Internal Medicine, La Paz University Hospital, Hospital La Paz Institute for Health Research, Biomedical Research Networking Center for Infectious Diseases, Madrid, Spain.
Roberto OrtizBliss Healthcare Services, Orlando, Florida, USA.
Mark UnderwoodClinical Development, ViiV Healthcare, Durham, North Carolina, USA.
Chris M ParryClinical Development, ViiV Healthcare, London, UK.
Richard GroveStatistics, GSK, London, UK.
V Paul DiMondiScientific Communications and Medical Education, ViiV Healthcare, Durham, North Carolina, USA.
Bryn JonesGlobal Medical Affairs, ViiV Healthcare, London, UK.
Michelle KisareGlobal Medical Affairs, ViiV Healthcare, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Through 144 weeks in GEMINI-1/-2 and 48 weeks in STAT, dolutegravir/lamivudine demonstrated high rates of virologic efficacy and a good safety profile in individuals naive to antiretroviral therapy across baseline viral load categories, including in those with very high baseline viral load (≥500 000 copies/mL).

Indexed as

2-drug regimenART naivehigh viral loadtest-and-treat settingvirologic suppression

Identifiers

PMID40134635
PMCPMC11935529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.